adamantane and ATLL
adamantane has been researched along with ATLL in 4 studies
Research
Studies (4)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Darwiche, N; Dbaibo, G; Ghandour, B; Pisano, C | 1 |
| Abdel-Samad, R; Bazarbachi, A; Darwiche, N; Dbaibo, G; El Hajj, H; Ghandour, B; Ghantous, A; Hall, WW; Hasegawa, H; Jabbour, M; Khalil, B; Nasr, R; Pisano, C; Shahine, S; Sinjab, A; Zaatari, G | 1 |
| Césaire, R; Meniane, JC | 1 |
| Avramis, IA; Avramis, VI; Laug, WE; Sausville, EA | 1 |
Other Studies
4 other study(ies) available for adamantane and ATLL
| Article | Year |
|---|---|
Restoration of ceramide de novo synthesis by the synthetic retinoid ST1926 as it induces adult T-cell leukemia cell death.
Topics: Adamantane; Antineoplastic Agents; Cell Death; Ceramides; Cinnamates; Enzyme Activation; Gene Products, tax; Human T-lymphotropic virus 1; Humans; Jurkat Cells; Leukemia-Lymphoma, Adult T-Cell; Oxidoreductases; Proteolysis; Proto-Oncogene Proteins c-bcl-2; Time Factors | 2020 |
Preclinical efficacy of the synthetic retinoid ST1926 for treating adult T-cell leukemia/lymphoma.
Topics: Adamantane; Animals; Antineoplastic Agents; Apoptosis; Caspases; Cell Cycle Checkpoints; Cell Line, Transformed; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cinnamates; Disease Models, Animal; DNA Damage; Drug Evaluation, Preclinical; Gene Expression Regulation, Neoplastic; Gene Products, tax; Humans; Leukemia-Lymphoma, Adult T-Cell; Leukemic Infiltration; Mice; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2014 |
ST1926 repression of Tax: ATL targeted treatment?
Topics: Adamantane; Animals; Antineoplastic Agents; Cinnamates; Humans; Leukemia-Lymphoma, Adult T-Cell | 2014 |
Determination of drug synergism between the tyrosine kinase inhibitors NSC 680410 (adaphostin) and/or STI571 (imatinib mesylate, Gleevec) with cytotoxic drugs against human leukemia cell lines.
Topics: Adamantane; Antimetabolites, Antineoplastic; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Cytarabine; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Humans; Hydroquinones; Imatinib Mesylate; Leukemia-Lymphoma, Adult T-Cell; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Vascular Endothelial Growth Factor A; Vidarabine Phosphate | 2003 |